Search Results
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine and School of Medicine, Seoul, Republic of Korea
Search for other papers by Meihua Jin in
Google Scholar
PubMed
Division of Endocrinology and Metabolism, Department Internal Medicine, Dankook University College of Medicine, Cheonan, Republic of Korea
Search for other papers by Ahreum Jang in
Google Scholar
PubMed
Search for other papers by Chae A Kim in
Google Scholar
PubMed
Search for other papers by Tae Yong Kim in
Google Scholar
PubMed
Search for other papers by Won Bae Kim in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Min Ji Jeon in
Google Scholar
PubMed
Search for other papers by Won Gu Kim in
Google Scholar
PubMed
gland ( 1 , 2 ). Current treatment options for patients with Graves’ hyperthyroidism include antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, and surgery ( 1 , 3 , 4 ). Although geographical difference exists, ATD is the preferred first
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by J Karmisholt in
Google Scholar
PubMed
Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
Search for other papers by S L Andersen in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by I Bulow-Pedersen in
Google Scholar
PubMed
Search for other papers by A Krejbjerg in
Google Scholar
PubMed
Search for other papers by B Nygaard in
Google Scholar
PubMed
Department of Clinical Institute, Aalborg University, Aalborg, Denmark
Search for other papers by A Carlé in
Google Scholar
PubMed
Primers 2020 6 52. ( https://doi.org/10.1038/s41572-020-0184-y ) 3 Abraham P Avenell A McGeoch SC Clark LF Bevan JS . Antithyroid drug regimen for treating Graves’ hyperthyroidism . Cochrane Database of Systematic Reviews 2010 2010 CD003420
Search for other papers by Marta Nascimento Soares in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Department of Surgery and Physiology, Cardiovascular Research Unit, Faculty of Medicine from the University of Porto, Porto, Portugal
Search for other papers by Marta Borges-Canha in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Institute for Research Innovation in Health, University of Porto, Porto, Portugal
Search for other papers by Celestino Neves in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Department of Surgery and Physiology, Cardiovascular Research Unit, Faculty of Medicine from the University of Porto, Porto, Portugal
Search for other papers by João Sérgio Neves in
Google Scholar
PubMed
Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, Porto, Portugal
Institute for Research Innovation in Health, University of Porto, Porto, Portugal
Search for other papers by Davide Carvalho in
Google Scholar
PubMed
, smoking habits, treatment for Graves’ disease (type of antithyroid drug, maximum dose, duration and number of iodine ablative doses, and thyroidectomy), diagnosis of ophthalmopathy, diagnosis of dermopathy, thyroid ultrasound results, results of biopsies
Search for other papers by Yiyun Cui in
Google Scholar
PubMed
Search for other papers by Jinlong Chen in
Google Scholar
PubMed
Search for other papers by Rui Guo in
Google Scholar
PubMed
Search for other papers by Ruize Yang in
Google Scholar
PubMed
Search for other papers by Dandan Chen in
Google Scholar
PubMed
Search for other papers by Wei Gu in
Google Scholar
PubMed
Search for other papers by Francis Manyori Bigambo in
Google Scholar
PubMed
Search for other papers by Xu Wang in
Google Scholar
PubMed
Introduction Graves' disease (GD) in children has attracted worldwide attention. Antithyroid drug (ATD) has been recommended by 2022 European Thyroid Association Guideline as the first-line therapy for GD children ( 1 ). Since propylthiouracil
Search for other papers by Stefan Matei Constantinescu in
Google Scholar
PubMed
Search for other papers by Julien Hospel in
Google Scholar
PubMed
Search for other papers by Chantal Daumerie in
Google Scholar
PubMed
Search for other papers by Orsalia Alexopoulou in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Maria-Cristina Burlacu in
Google Scholar
PubMed
. Journal of Clinical Endocrinology and Metabolism 1989 68 1097 – 1100 . ( https://doi.org/10.1210/jcem-68-6-1097 ) 12 Katahira M & Ogata H . Thyroglobulin autoantibodies are associated with refractoriness to antithyroid drug treatment for Graves
Institute of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Search for other papers by Peter F Berglund in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Göteborg, Sweden
Gothenburg Centre for Person Centred-Care (GPCC), Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
with the local treatment scheme for premenopausal female adult patients with GD where all patients received either antithyroid drugs (ATD) or surgery with previous ATD treatment. As an exception, one patient was treated with radioactive iodine
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Search for other papers by Agneta Lindo in
Google Scholar
PubMed
Department of Endocrinology and Diabetes, Örebro University Hospital, Örebro, Sweden
Search for other papers by Anne Breikert in
Google Scholar
PubMed
Thyroid Federation International, Kungsbacka, Sweden
Search for other papers by Peter Lakwijk in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Christin Lundberg in
Google Scholar
PubMed
Swedish Thyroid Association, Stockholm, Sweden
Search for other papers by Katarina Lunner in
Google Scholar
PubMed
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
The National Task Force in Hyperthyroidism, Swedish National System for Knowledge-Driven Management, Umeå, Sweden
Sweden and Wallenberg Center for Molecular and Translational Medicine, Västra Götaland Region, Göteborg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
. A New Zealand study ( 14 ) has examined the level of patient preference in determining which type of treatment to proceed with. The most important factors for choosing therapy between antithyroid drugs (ATDs), surgery, or radioactive iodine (RAI
Search for other papers by Caiyan Mo in
Google Scholar
PubMed
Search for other papers by Han Chen in
Google Scholar
PubMed
Search for other papers by Qi Zhang in
Google Scholar
PubMed
Search for other papers by Ying Guo in
Google Scholar
PubMed
Search for other papers by Liyong Zhong in
Google Scholar
PubMed
function change, and treatment of case 1. ATD, antithyroid drugs; FT3, free tri-iodothyronine; FT4, free thyroxine; SSA, somatostatin analog; TRAb, thyroid-stimulating hormone receptor antibodies; TSH, thyroid-stimulating hormone; TSS, transsphenoidal
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, Japan
Search for other papers by Megumi Fujikawa in
Google Scholar
PubMed
Search for other papers by Ken Okamura in
Google Scholar
PubMed
high prevalence of insufficient decline or re-elevation of thyroid hormone levels, the so-called ‘escape phenomenon from the Wolff-Chaikoff effect’ ( 7 , 8 ), was observed. Since the introduction of thionamide antithyroid drugs ( 9 ), the use of iodide
Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Birgitta Johansson in
Google Scholar
PubMed
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Search for other papers by Mats Holmberg in
Google Scholar
PubMed
Department of Pedagogical, Curricular and Professional Studies, Faculty of Education, University of Gothenburg, Gothenburg, Sweden
Search for other papers by Simon Skau in
Google Scholar
PubMed
Search for other papers by Helge Malmgren in
Google Scholar
PubMed
Wallenberg’s Centre of Molecular and Translational Medicine, Region Västra Götaland, Sweden
Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Helena Filipsson Nyström in
Google Scholar
PubMed
included from September 2011 to October 2019 at the Department of Endocrine Research, Sahlgrenska University Hospital, Gothenburg, Sweden. Patients were included within 2 weeks after starting treatment with antithyroid drugs (ATD, thiamazole). All patients